Bouchard P, Al-Masrouri S, Demyttenaere S, Court O, Andalib A Long-term Impact of Bariatric Surgery on Major Adverse Cardiovascular Events in Patients with Obesity, Diabetes and Hypertension: a Population-level Study. Obes Surg. 2022 Mar;32(3):771-778. doi: 10.1007/s11695-021-05849-1. Epub 2022 Jan 21.
Ferraioli G, Kumar V, Ozturk A, Nam K, de Korte CL, Barr RG US Attenuation for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative. Radiology. 2022 Mar;302(3):495-506. doi: 10.1148/radiol.210736. Epub 2022 Jan 25.
Kim M, Kang BK, Jun DW Comparison of conventional sonographic signs and magnetic resonance imaging proton density fat fraction for assessment of hepatic steatosis. Sci Rep. 2018 May 17;8(1):7759. doi: 10.1038/s41598-018-26019-x.
Labyed Y, Milkowski A Novel Method for Ultrasound-Derived Fat Fraction Using an Integrated Phantom. J Ultrasound Med. 2020 Dec;39(12):2427-2438. doi: 10.1002/jum.15364. Epub 2020 Jun 11.
Osawa H, Mori Y Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound. 1996 Jan;24(1):25-9. doi: 10.1002/(SICI)1097-0096(199601)24:13.0.CO;2-N.
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
Younossi ZM Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019 Mar;70(3):531-544. doi: 10.1016/j.jhep.2018.10.033. Epub 2018 Nov 9.
Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.